Comparison of Time Curves from Dynamic F-fluciclovine Positron Emission Tomography and Dynamic Contrast-enhanced Magnetic Resonance Imaging for Primary Prostate Carcinomas

Overview

Journal Phys Imaging Radiat Oncol

Specialty Oncology

Date 2021 Jan 18

PMID 33458405

Citations 4

Authors

Andreas Julius Tulipan

Ljiljana Vlatkovic

Eirik Malinen

Bjorn Brennhovd

Knut Hakon Hole

Agnes Kathrine Lie

Harald Bull Ragnum

Mona-Elisabeth Revheim

Therese Seierstad

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Multimodal imaging is increasingly included in the assessment of prostate cancer patients, and there is a need to study whether different techniques provide similar or complementary information. In the initial perfusion phase contrast agents and radioactive labelled tracers act as blood-pool agents and may show similar characteristics. The purpose of the current work was to compare time-activity- and time-concentration-curves (TCs) of dynamic F-fluciclovine (F-anti-1-amino-2-[F]-fluorocyclobutane-1-carboxylic acid, FACBC) positron emission tomography (PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE MRI).

Materials And Methods: Dynamic FACBC PET and DCE MRI were performed on 22 patients with intermediate or high-risk prostate cancer within 23 days prior to robot-assisted laparoscopic prostatectomy. Index tumour was delineated in the images using whole mount tissue sections as reference standard. Tumour TCs from PET and MRI were compared visually and quantitatively by calculating correlation coefficients between the curves at different time points after injection.

Results: For the first minute post injection, the mean correlation coefficient between the TCs from PET and MRI was 0.92 (range; 0.75-0.99). After the first minute, MRI showed washout while PET showed plateau kinetics.

Conclusion: Dynamic FACBC and DCE MRI showed similar wash-in time curve characteristics. At later time points, FACBC plateaued whereas MR contrast medium washed out. In DCE MRI, the usefulness of wash-in information is well documented. Whether wash-in information from dynamic FACBC can provide added value remains to be documented.

Citing Articles

Blanching Defects at the Pressure Points: Observations from Dynamic Total-Body PET/CT Studies.

Abdelhafez Y, Mcbride K, Leung E, Hunt H, Spencer B, Lopez J J Nucl Med Technol. 2022; .

PMID: 35440473 PMC: 9745988. DOI: 10.2967/jnmt.122.263905.

Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard.

Hole K, Tulipan A, Reijnen J, Hernes E, Vlatkovic L, Lie A Am J Nucl Med Mol Imaging. 2021; 11(5):387-394.

PMID: 34754609 PMC: 8569330.

Imaging science and development in modern high-precision radiotherapy.

Thorwarth D, Muren L Phys Imaging Radiat Oncol. 2021; 12:63-66.

PMID: 33458297 PMC: 7807660. DOI: 10.1016/j.phro.2019.11.008.

Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy.

Grosu A, van der Heide U Phys Imaging Radiat Oncol. 2021; 11:61-62.

PMID: 33458279 PMC: 7807567. DOI: 10.1016/j.phro.2019.09.001.

References

Canet E, Casali C, Desenfant A, An M, Corot C, Obadia J . Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn Reson Med. 2000; 43(3):403-9. DOI: 10.1002/(sici)1522-2594(200003)43:3<403::aid-mrm12>3.0.co;2-6. View

Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M . Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011; 52(5):822-9. DOI: 10.2967/jnumed.110.086074. View

Sorensen J, Owenius R, Lax M, Johansson S . Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2012; 40(3):394-402. DOI: 10.1007/s00259-012-2291-9. View

Barentsz J, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G . ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22(4):746-57. PMC: 3297750. DOI: 10.1007/s00330-011-2377-y. View

Epstein J . An update of the Gleason grading system. J Urol. 2009; 183(2):433-40. DOI: 10.1016/j.juro.2009.10.046. View

Elschot M, Selnaes K, Sandsmark E, Kruger-Stokke B, Storkersen O, Tessem M . A PET/MRI study towards finding the optimal [F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016; 44(4):695-703. DOI: 10.1007/s00259-016-3562-7. View

Hotker A, Mazaheri Y, Aras O, Zheng J, Moskowitz C, Gondo T . Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI. AJR Am J Roentgenol. 2016; 206(4):756-63. PMC: 5479568. DOI: 10.2214/AJR.15.14912. View

Evelhoch J . Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999; 10(3):254-9. DOI: 10.1002/(sici)1522-2586(199909)10:3<254::aid-jmri5>3.0.co;2-9. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

10.

Panebianco V, Barchetti F, Barentsz J, Ciardi A, Cornud F, Futterer J . Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging. 2015; 6(6):611-30. PMC: 4656245. DOI: 10.1007/s13244-015-0426-9. View

11.

Turkbey B, Mena E, Shih J, Pinto P, Merino M, Lindenberg M . Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology. 2014; 270(3):849-56. PMC: 4263644. DOI: 10.1148/radiol.13130240. View

12.

Hole K, Axcrona K, Lie A, Vlatkovic L, Geier O, Brennhovd B . Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. Eur Radiol. 2012; 23(4):1158-66. PMC: 3599204. DOI: 10.1007/s00330-012-2669-x. View

13.

Oka S, Okudaira H, Yoshida Y, Schuster D, Goodman M, Shirakami Y . Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2011; 39(1):109-19. DOI: 10.1016/j.nucmedbio.2011.06.008. View

14.

Hole K, Larsen S, Groholt K, Giercksky K, Ree A . Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer. Radiother Oncol. 2013; 107(2):178-83. DOI: 10.1016/j.radonc.2013.03.017. View

15.

Schuster D, Taleghani P, Nieh P, Master V, Amzat R, Savir-Baruch B . Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging. 2013; 3(1):85-96. PMC: 3545368. View

16.

Vos E, Litjens G, Kobus T, Hambrock T, Hulsbergen-van de Kaa C, Barentsz J . Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol. 2013; 64(3):448-55. DOI: 10.1016/j.eururo.2013.05.045. View

17.

Haworth A, Williams S . Focal therapy for prostate cancer: the technical challenges. J Contemp Brachytherapy. 2017; 9(4):383-389. PMC: 5611463. DOI: 10.5114/jcb.2017.69809. View

18.

Bonekamp D, Macura K . Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. Top Magn Reson Imaging. 2009; 19(6):273-84. DOI: 10.1097/RMR.0b013e3181aacdc2. View

19.

Segawa A, Nagamori S, Kanai Y, Masawa N, Oyama T . L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer. Mol Clin Oncol. 2014; 1(2):274-280. PMC: 3956267. DOI: 10.3892/mco.2012.54. View

20.

Schuster D, Votaw J, Nieh P, Yu W, Nye J, Master V . Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48(1):56-63. View